Genolution Inc.

Equities

A225220

KR7225220003

Biotechnology & Medical Research

End-of-day quote Korea S.E. Other stock markets 06:00:00 2024-06-04 pm EDT			5-day change	1st Jan Change
3,905 ^KRW	+0.26%		+1.03%	+1.83%

May. 07	Genolution Inc. announced that it expects to receive CNY 750.00284 million in funding from RICO Asset Management Co., Ltd.	CI
Jan. 09	Tranche Update on Genolution Inc.'s Equity Buyback Plan announced on July 10, 2023.	CI

Tranche Update on Genolution Inc.'s Equity Buyback Plan announced on July 10, 2023.

October 13, 2023 at 01:04 am EDT

From July 10, 2023 to September 30, 2023, the company has repurchased 284,103 shares, representing 1.53% for KRW 1,225.83 million. With this, the company has completed the repurchase of 284,103 shares, representing 1.53% for KRW 1,225.83 million under the buyback announced on July 10, 2023.

Latest news about Genolution Inc.

Genolution Inc. announced that it expects to receive CNY 750.00284 million in funding from RICO Asset Management Co., Ltd.	May. 06	CI
Tranche Update on Genolution Inc.'s Equity Buyback Plan announced on July 10, 2023.	Jan. 09	CI
Tranche Update on Genolution Inc.'s Equity Buyback Plan announced on July 10, 2023.	Jan. 09	CI
Genolution Inc.'s Equity Buyback announced on July 10, 2023, has expired with 477,003 shares, representing 2.59% for KRW 1,989.17 million.	Jan. 08	CI
Tranche Update on Genolution Inc.'s Equity Buyback Plan announced on July 10, 2023.	23-10-13	CI
Genolution Inc. announces an Equity Buyback for KRW 2,000 million worth of its shares.	23-07-10	CI
Genolution Inc. authorizes a Buyback Plan.	23-07-09	CI
Genolution Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-15	CI
Tranche Update on Genolution Inc.'s Equity Buyback Plan announced on October 6, 2022.	23-04-05	CI
Tranche Update on Genolution Inc.'s Equity Buyback Plan announced on October 6, 2022.	23-04-05	CI
Genolution Inc.'s Equity Buyback announced on October 6, 2022, has expired with 201,596 shares, representing 2.20% for KRW 1,999.70 million.	23-04-04	CI
Tranche Update on Genolution Inc.'s Equity Buyback Plan announced on October 6, 2022.	23-01-09	CI
Genolution Inc. announces an Equity Buyback for KRW 2,000 million worth of its shares.	22-10-05	CI
Genolution Inc. authorizes a Buyback Plan.	22-10-05	CI
Genolution Inc.(KOSDAQ:A225220) dropped from S&P Global BMI Index	22-09-19	CI
Tranche Update on Genolution Inc.'s Equity Buyback Plan announced on November 23, 2021.	22-05-23	CI
Tranche Update on Genolution Inc.'s Equity Buyback Plan announced on November 23, 2021.	22-05-23	CI
Tranche Update on Genolution Inc.'s Equity Buyback Plan announced on November 23, 2021.	22-05-23	CI
Tranche Update on Genolution Inc.'s Equity Buyback Plan announced on November 23, 2021.	22-05-23	CI
Genolution Inc.'s Equity Buyback announced on November 23, 2021, has expired with 126,153 shares, representing 1.34% for KRW 1,999.26 million.	22-05-22	CI
Genolution Inc.'s Equity Buyback announced on November 23, 2021, has expired with 201,989 shares, representing 2.14% for KRW 2,982.48 million.	22-05-22	CI
Genolution Inc.'s Equity Buyback announced on August 31, 2021, has expired.	22-03-13	CI
Tranche Update on Genolution Inc.'s Equity Buyback Plan announced on November 23, 2021.	22-02-25	CI
Tranche Update on Genolution Inc.'s Equity Buyback Plan announced on November 23, 2021.	22-02-25	CI
Genolution Inc. announces an Equity Buyback for KRW 3,000 million worth of its shares.	21-11-23	CI

Chart Genolution Inc.

Duration

Period

More charts

Company Profile

GENOLUTION INC. is a company principally engaged in the manufacture and distribution of molecular diagnostic equipment and products related ribonucleic acid interference (RNAi) research. The Companyâs products include automated nucleic acid extraction devices, nucleic acid extraction reagents and molecular diagnostic products. The Company also provides ribonucleic acid interference services. The Company distributes its products within domestic market and to overseas markets.

Sector

Biotechnology & Medical Research

Calendar

2024-08-08 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Bio Diagnostics & Testing

	1st Jan change	Capi.
GENOLUTION INC.	+1.83%	54.38M
GUARDANT HEALTH, INC.	+18.23%	3.43B
IOVANCE BIOTHERAPEUTICS, INC.	+2.28%	2.27B
BGI GENOMICS CO., LTD.	-19.52%	2.03B
VERACYTE, INC.	-19.74%	1.63B
MARAVAI LIFESCIENCES HOLDINGS, INC.	+32.21%	1.16B
CAREDX, INC	+17.21%	714M
SEEGENE, INC.	-9.39%	703M
ADAPTIVE BIOTECHNOLOGIES CORPORATION	-22.35%	500M
CURIOX BIOSYSTEMS CO., LTD	-1.29%	279M

Bio Diagnostics & Testing